Cadrenal Therapeutics CMO James J. Ferguson III resigns effective July 31, 2026

Cadrenal Therapeutics, Inc.

CMO James J. Ferguson III resigned; effective July 31, 2026.
Company is conducting a search for replacement.
Separation agreement includes salary through separation date and COBRA premium payments for 6 months.
Agreement includes general release of claims and non-disparagement clause.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.